|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009324,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0035052,
umls-concept:C0127615,
umls-concept:C0439851,
umls-concept:C0524527,
umls-concept:C1552596,
umls-concept:C1707455,
umls-concept:C1947931,
umls-concept:C2603343
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-8-30
|
|
pubmed:abstractText |
Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1536-4844
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1567-74
|
|
pubmed:meshHeading |
pubmed-meshheading:20049950-Adolescent,
pubmed-meshheading:20049950-Adult,
pubmed-meshheading:20049950-Aged,
pubmed-meshheading:20049950-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:20049950-Chemistry, Pharmaceutical,
pubmed-meshheading:20049950-Colitis, Ulcerative,
pubmed-meshheading:20049950-Double-Blind Method,
pubmed-meshheading:20049950-Female,
pubmed-meshheading:20049950-Follow-Up Studies,
pubmed-meshheading:20049950-Humans,
pubmed-meshheading:20049950-Hydrogen-Ion Concentration,
pubmed-meshheading:20049950-Male,
pubmed-meshheading:20049950-Mesalamine,
pubmed-meshheading:20049950-Middle Aged,
pubmed-meshheading:20049950-Pharmaceutical Preparations,
pubmed-meshheading:20049950-Remission Induction,
pubmed-meshheading:20049950-Severity of Illness Index,
pubmed-meshheading:20049950-Survival Rate,
pubmed-meshheading:20049950-Time Factors,
pubmed-meshheading:20049950-Treatment Outcome,
pubmed-meshheading:20049950-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.
|
|
pubmed:affiliation |
Digestive Disease Center of Excellence, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
